Alzheimer's Disease And Dementia

Abnormalities in Genes Linked to IRSP in Alzheimer Disease

Abnormalities in Genes Linked to IRSP in Alzheimer Disease

Individuals with Alzheimer disease have abnormalities and reductions in gene expression in the parahippocampal gyri that map to genes associated with the insulin receptor signaling pathway.

Alzheimer Disease Biomarkers Expose Individuals to Long-Term Care Insurance Denial

Alzheimer Disease Biomarkers Expose Individuals to Long-Term Care Insurance Denial

By

Approximately 5.5 million Americans have Alzheimer disease or dementia.

Critical Illness and the Brain: Managing Risk for Cognitive Adverse Effects

Critical Illness and the Brain: Managing Risk for Cognitive Adverse Effects

By

The results highlight the importance of evaluating and monitoring cognitive function in individuals with recent critical illness or major infections, especially if they are already at risk for dementia.

Multiple Births Associated With Greater Late-Life Risk for Alzheimer Disease

Multiple Births Associated With Greater Late-Life Risk for Alzheimer Disease

By

Grand multiparity was associated with significantly worse Mini-Mental State Examination scores compared with those with 1 to 4 completed pregnancies.

Positive Link Between Air Pollution, Diagnosis of Dementia

Positive Link Between Air Pollution, Diagnosis of Dementia

There is a positive association between residential levels of air pollution and being diagnosed with dementia.

Age, Sex, <i>APOE</i> Genotype Identify Alzheimer's, Dementia Risk

Age, Sex, APOE Genotype Identify Alzheimer's, Dementia Risk

Age, sex and apolipoprotein E genotype can identify groups at high 10-year risk for Alzheimer disease and all dementia.

Multiple Pathways Explain Age-Linked Increase in Dementia Risk

Multiple Pathways Explain Age-Linked Increase in Dementia Risk

Multiple pathways account for the age-related increases in dementia risk.

Prevalence of Alzheimer's, Related Dementia Set to Double

Prevalence of Alzheimer's, Related Dementia Set to Double

The burden of Alzheimer disease and related dementias is expected to increase to 3.3% in the United States by 2060.

Retinal Abnormalities May Indicate Preclinical Alzheimer's

Retinal Abnormalities May Indicate Preclinical Alzheimer's

Retinal microvascular abnormalities are identified in cognitively healthy individuals who have biomarkers positive for Alzheimer disease.

PET Imaging Can Measure Synaptic Loss From Alzheimer's

PET Imaging Can Measure Synaptic Loss From Alzheimer's

Positron emission tomographic imaging can directly measure synaptic loss with Alzheimer disease.

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

Treatment for Alzheimer-Related Agitation Gets Fast Track Status

By

Currently, there are no approved treatments for behavioral symptoms in Alzheimer disease.

Midlife Cognition, Vascular Health Predict Dementia and Cognitive Impairment Later in Life

Midlife Cognition, Vascular Health Predict Dementia and Cognitive Impairment Later in Life

By

Investigators reviewed data from patients aged 45 to 64 years who were enrolled in the Atherosclerosis Risk in Communities Study and who attended additional visits for cognitive function evaluation and repeat cardiovascular risk factor assessment.

Positive PET Results and Hippocampal Volume Predict Progression From MCI to Dementia

Positive PET Results and Hippocampal Volume Predict Progression From MCI to Dementia

By

An international team of investigators assessed the ability of flutemetamol F 18-labeled PET and other biomarkers to predict risk of clinical progression from amnestic mild cognitive impairment to probable Alzheimer disease.

Amyloid PET Tied to Diagnostic Changes in Memory Clinic Cohort

Amyloid PET Tied to Diagnostic Changes in Memory Clinic Cohort

For an unselected memory clinic cohort, amyloid PET results are associated with changes in etiology, diagnostic confidence, and patient treatment.

Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds

Herpesvirus Abundant in Alzheimer Disease Brain, New Study Finds

By

While hundreds of published reports have made an argument for an association between Alzheimer disease and bacteria and viruses, the suggestion of a viral contribution to Alzheimer disease has not always been well received by the greater research community.

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

Trials for Investigational Alzheimer's Tx Lanabecestat Discontinued

By

Phase 3 clinical trials for lanabecestat (Eli Lilly and AstraZeneca), an investigational Alzheimer disease treatment, are being discontinued for futility.

Higher Blood Pressure at Mid-Life Increases Dementia Risk

Higher Blood Pressure at Mid-Life Increases Dementia Risk

The risk of dementia is increased in 50-year-olds with blood pressure ≥130 mm Hg, which is below the current threshold for hypertension.

Lifetime Risks Temper Biomarker Tests for Alzheimer Disease Dementia

Lifetime Risks Temper Biomarker Tests for Alzheimer Disease Dementia

The lifetime risks of Alzheimer disease dementia vary considerably by age, gender, and the preclinical or clinical disease state.

Polyphenol-Rich Diet May Reduce Dementia Risk in Older Adults

Polyphenol-Rich Diet May Reduce Dementia Risk in Older Adults

By

There was an observable pattern with combined polyphenol intake and risk for dementia in the study cohort.

Studies Halted for Alzheimer's Candidate Atabecestat Due to Safety Concerns

Studies Halted for Alzheimer's Candidate Atabecestat Due to Safety Concerns

By

Janssen announced that the Company will no longer continue studying atabecestat, an investigational treatment for asymptomatic patients at risk for developing Alzheimer disease.

Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics

Mortality in Alzheimer Disease Not Strongly Associated With Antipsychotics

By

These results suggest that antipsychotic exposure has no impact on relative mortality.

FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions

FNIH Launches Project to Identify Biosignatures of Neurodegenerative, Psychiatric Conditions

By

Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.

Treating Apathy in Alzheimer Disease Patients: A Meta-Analysis

Treating Apathy in Alzheimer Disease Patients: A Meta-Analysis

By

Methylphenidate demonstrated an improvement in apathy vs placebo when measured by the apathy evaluation scale, in addition, methylphenidate showed possible improvement in cognition.

Certain Anticholinergic Drugs Appear to Raise Dementia Risk

Certain Anticholinergic Drugs Appear to Raise Dementia Risk

Use of anticholinergic drugs may be tied to a future diagnosis of dementia.

Melanoma, Nonmelanoma Skin Cancer Associated With Reduced Risk for Alzheimer's

Melanoma, Nonmelanoma Skin Cancer Associated With Reduced Risk for Alzheimer's

By

Additional examination of these relationships is warranted to help clarify the complex biologic and psychosocial interactions among Alzheimer disease, malignant melanoma, and nonmelanoma skin cancer.

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

Phase 3 Results Released for Investigational Alzheimer Disease Treatment

By

Results showed that after 18-months, there was no significant statistical difference in cognitive or functional outcomes between those patients taking azeliragon and the placebo group.

Concern for Employer, Insurance Discrimination for Alzheimer's Patients

Concern for Employer, Insurance Discrimination for Alzheimer's Patients

About half of adults surveyed expect a man with mild Alzheimer dementia to be discriminated against.

Nurse Education Improves Post-Op Survival in Dementia Patients

Nurse Education Improves Post-Op Survival in Dementia Patients

Findings show lower post-surgical mortality among patients with Alzheimer's disease.

Preclinical Alzheimer's Identified With Molecular Markers

Preclinical Alzheimer's Identified With Molecular Markers

Molecular markers can identify changes associated with the disease before clinical onset for young adults with autosomal dominant AD.

Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued

Trial of Verubecestat for Prodromal Alzheimer Disease Discontinued

By

Merck announced the discontinuation of the Phase 3 APECS study for the treatment of AD.

Sign Up for Free e-newsletters



CME Focus